Xin Li, Ph.D.

 

Research Assistant Professor
Ph.D., Pathology & Physiology, College of Medicine, Zhejiang University, ChinaLiXin

Postdoctoral fellowship, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences

Selected Publications:

van Rhee F, Szmania S, Dillon M, van Abbema A, Li X, Stone M, Garg TK, Shi J, Bost-Moreno AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy J, Barlogie B, Yaccoby S, Afar DEH. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics. 2009 Sep 8(9): 2616-24.

Li X, Ling W, Pennisi A, Khan S, Yaccoby S. Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Lett. 2009 May 14; 284 (2): 175-181.

Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood. 2008 Jul 1; 112(1):159-68.

Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD Jr. Atacicept (TACI-Ig) inhibits growth of TACI high primary myeloma cells in SCID-hu mice and in co-culture with osteoclasts. Leukemia. 2008 Feb; 22(2):406-13.

Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and nonhyperdiploid human myeloma cell lines. British Journal of Haematology. 2007,138: 802-811